The integration of inhaled nitric oxide therapy addresses critical needs for patients suffering from pulmonary hypertension and severe oxygenation failure. By relaxing blood vessels in the lungs, the gas improves oxygenation and lowers pulmonary pressure, reducing strain on the heart. The capability is particularly vital for infants and burn patients experiencing respiratory distress who require stable, hospital-level intervention during transit.
AirCARE1 Gains FAA Approval to Administer Inhaled Nitric Oxide in Flight
AirCARE1 has secured Federal Aviation Administration authorization to carry and administer inhaled nitric oxide aboard its Learjet 60 fleet. This regulatory milestone allows the air ambulance provider to maintain specialized respiratory support for medically fragile patients during long-range transport, ensuring continuous care from bedside to bedside.
Christina Kennedy, Program Director and Chief Flight Nurse, spearheaded the clinical and operational integration required to meet FAA safety standards for hazardous materials transport. The process involved implementing specialized equipment, rigorous crew training, and aircraft-specific protocols. Founder Denise Waye noted that the move reflects the company's focus on advancing air medicine through formal, regulated operating systems rather than informal practice. AirCARE1, a CAMTS-accredited provider, operates its Learjet 60 aircraft as flying intensive care units, serving patients across North, Central, and South America.
Comments (0)
No comments yet. Be the first!